• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Nevirapine
    2 Drugs classified under this active ingredient


    All the Active Ingredient Drugs

    Viramune 200 mg Tablets
    Boehringer Ingelheim
    RX
    partial basket chart
    Viramune 200 mg Tablets

    Non-Nucleoside Reverse Transcriptase Inhibitors. Nevirapine (as anhydrous) 200 mg.
    TABS. (anhydrous): 60 x 200 mg. 1
    tab×1/d for 14 days, follow. by 1
    tab×2/d. in comb. with other
    antiretrovir. ther.
    For use in comb. with other antiretrov.
    agents for the tmt. of HIV-1 infec. in
    adults, adolescents, and child. of any age.
    Most of the experience with Nevirapine is
    in comb. with nucleoside reverse
    transcriptase inhibitors (NRTIs). The
    choice of a subsequent ther. after Nevirapine should be based on clinical
    experience and resistance testing.
    C/I: Hypersens., Readministr. to pts. who
    required permanent discount. for severe
    rash, rash accompanied by constitutional
    sympts., hypersens. react., or clinical
    hepatitis due to nevirapine, severe
    hepatic impair. (Child-Pugh C) or pretreatment ASAT or ALAT > 5 ULN until
    baseline ASAT/ALAT are stabilised < 5
    ULN. Readministr. to pts who previous. had
    ASAT or ALAT > 5 ULN during nevirapine ther. and had recur. of liver function abnormalit. upon readministr. of nevirapine, Coadministr. with herbal preparations containing St. John’s wort (Hypericum perforatum) due to risk of decreased plasma concentr. and reduced clinical effects of nevirapine.

    Viramune 50 mg/5 ml Oral Suspension
    Boehringer Ingelheim
    RX
    partial basket chart
    Viramune 50 mg/5 ml Oral Suspension

    Non-Nucleoside Reverse Transcriptase Inhibitors. Nevirapine (as hemihydrate) 50 mg/5 ml.
    SUSP.: 240 ml x 10 mg/ml.
    Child.: 0 - 8 yrs.: 4 mg/kg×1/d. for 14
    days, follow. by 7 mg/kg×2/d; 8 yrs.
    and over: 4 mg/kg×1/d for 2 wks.,
    follow. by 4 mg/kg×2/d. Alternat.
    dosing, child.:– 150 mg/m2×1/d for 14
    days, follow. by 150 mg/m2×2/d. max.
    dly. dose: 400 mg. See lit.
    For use in comb. with other antiretrov.
    agents for the tmt. of HIV-1 infec. in
    adults, adolescents, and child. of any age.
    Most of the experience with Nevirapine is
    in comb. with nucleoside reverse
    transcriptase inhibitors (NRTIs). The
    choice of a subsequent ther. after Nevirapine should be based on clinical
    experience and resistance testing.
    C/I: Hypersens., Readministr. to pts. who
    required permanent discount. for severe
    rash, rash accompanied by constitutional
    sympts., hypersens. react., or clinical
    hepatitis due to nevirapine, severe
    hepatic impair. (Child-Pugh C) or pretreatment ASAT or ALAT > 5 ULN until
    baseline ASAT/ALAT are stabilised < 5
    ULN. Readministr. to pts who previous. had
    ASAT or ALAT > 5 ULN during nevirapine ther. and had recur. of liver function abnormalit. upon readministr. of nevirapine, Coadministr. with herbal preparations containing St. John’s wort (Hypericum perforatum) due to risk of decreased plasma concentr. and reduced clinical effects of nevirapine.

    CLOSE